3 Houston innovators to know this week

Who's who

The three Houston innovators to know this week represent new, exciting things for the innovation ecosystem. Courtesy photos

The movers and shakers within the Houston innovation ecosystem come from all kinds of industries — from private equity to supercomputing. This week's innovators to know reflect that industry diversity and are bringing something new to the table.

Jon Nordby, managing director of Houston's MassChallenge Texas chapter

Jon Nordby, former exec at Houston Exponential, will lead the inaugural Houston MassChallenge cohort. Courtesy of MassChallenge

Jon Nordby, who recently served as Houston Exponential's director of strategy since its launch, was named as the managing director of MassChallenge Texas in Houston, a zero-equity startup accelerator.

"MassChallenge's not-for-profit, no equity model is uniquely suited to accelerate the development of Houston's innovation ecosystem and is the foundation early-stage startups need to get to the point of disruption or pivot as fast as possible," says Nordby in a release.

Before HX, Nordby served as vice president of talent and innovation at the Greater Houston Partnership, and was essential in creating the organization's Innovation Initiative. Click here to learn more about the appointment.

Matthew Lamont, managing director at DownUnder GeoSolutions

Matthew Lamont is managing director at DownUnder GeoSolutions which just opened its new, powerful data center west of Houston. Courtesy of DUG

Matthew Lamont isn't technically a Houstonian, but the managing director of Perth, Australia-based DownUnder GeoSolutions gets the honorary title for bringing one of the world's most powerful supercomputers, nicknamed Bubba, to the Houston area. In fact, perhaps Lamont accepts the recognition on behalf of Bubba, who — while inanimate — is definitely a Houstonian.

DUG is heavily investing in Houston, and Bubba is just the start. The company plans to start on a friend for Bubba later this year and bring an even more powerful supercomputer to the market by 2021. Read more about Lamont, Bubba, and all that DUG is doing in Houston here.

Taseer Badar, founder and CEO of ZT Corporate

Taseer Badar is in the business of making money. Courtesy of ZT Corporate

Taseer Badar will shoot it to you straight: Houston startups struggling to find capital might need to look nationally or globally.

"Investors in Houston want positive earnings before interest, tax, and amortization," he says. "But that doesn't mean it's not possible in New York, Dallas, Austin, or other cities. There are technology conferences everywhere, that's a great way to get known as a startup."

As CEO and founder of ZT Corporate with 1,000 investors to manage, he knows private equity, and what it takes to invest. Read more about Badar here.

Taseer Badar is in the business of making money. Courtesy of ZT Corporate

Private equity executive talks diversifying and Houston's investment ecosystem

Featured innovator

It's Taseer Badar's job to keep 1,000 investors happy. As CEO and founder of ZT Corporate, that's just a day in the life for him.

Badar has been in the business for over 20 years, and before that, he was on Wall Street as a financial adviser for Morgan Stanley. He realized the dollar went further in his hometown of Houston, so he came back. He started advising on business plans for people he knew, and earned a lot of loyalty from these early entrepreneurs, and grew ZT from there. He found his way into health care, which made up a good majority of his holdings, until about four years ago when he diversified his company and got into the automotive industry.

Last year, the company celebrated its largest exit — Altus Infusion — and acquisition — six Neighbors ER clinics. He created a nonprofit foundation —The Altus Foundation — and raised over $1 million for assistance for underserved families. Over the past 20 years, Badar grew his company from $28 million in revenue to over $600 million — with no end in sight.

Badar spoke with InnovationMap about his career, the health care industry, and what its like to be in private equity in Houston.

InnovationMap: You've recently diversified to include a startup in your portfolio. Tell me about that company.

Taseer Badar: We have group called Accountable Care as an entity, which we are sustaining analytics. It's the opposite of a fee for service business. It used to be that if a patient got sick, we treat you. Now, it's preventive care. We have a pilot of around 40,000 patients right now. It has a lot of potential and it keeps people healthier. How it works is insurance companies pay you to keep their consumer healthy. Let's say an insurance company pays us $100, and we treat them for $85 and keep the rest for our investors.

IM: How does Houston’s investment ecosystem compare to other cities you work in?

TB: For me, it was really hard to move into that. I am very traditional. We're not a risk-based company; we're very risk averse. For me, this fit into our business. It fell in my lap. I do think generally it's a conservative ecosystem, in my opinion. We're not San Francisco — we're not built like that. Not saying no one does it. I was in New York, and those are the guys who understand [venture capital]. In Houston, we understand oil and gas, and we understand medical and real estate. I think we're way off for the startup [investment] here.

IM: With that being said, what is your advice for tech startups seeking capital, then?

TB: Investors in Houston want positive earnings before interest, tax, and amortization. But that doesn't mean it's not possible in New York, Dallas, Austin, or other cities. There are technology conferences everywhere, that's a great way to get known as a startup.

IM: How have you seen the health care industry evolve?

TB: Texas is a state that has a lot of doctors that are entrepreneurial. I personally feel as though that a lot of the Obamacare, and the accountable care, a lot of practices have been bought by hospitals, so you don't see a lot of freestanding medical practices as much as I used to. At the same time, a lot of the younger doctors aren't as business oriented and want more work-life balance. Because there's less of them, there are opportunities for companies like mine to take care of them. When I started, Altus was one of 50 companies of its kind. Now, we are one of two or three standing in Houston with that type of model.

IM: What are the challenges of managing investors?

TB: We have a lot of retail investors. They are great, and it's much more relation based. But, at the same time, a very high-touch business. That requires a lot of time and effort in a relationship. It's a lot more managing of the process.

IM: What do you look for in an investor?

TB: We look for investors that are accredited investors, and we want someone who understands there's a time horizon, who are looking for an income and an exit play between three and seven years. Someone who understands risk and that it's not buying a stock that can be liquidated.

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings